

# **Biomedical Protocols for Free-ranging Brown Bears, Gray Wolves, Wolverines and Lynx**

*Editors*

**Jon M. Arnemo & Åsa Fahlman**

*Contributors*

**Per Ahlqvist, Roy Andersen, Henrik Andrén, Sven Brunberg, Arild Landa,  
Olof Liberg, John Odden, Jens Persson, Peter Segerström  
& Jon E. Swenson**



**Norwegian School of Veterinary Science, Tromsø, Norway**

**Revised: 21 August 2007**

## PREFACE

Compilation of this document was initiated by the Norwegian Directorate for Nature Management in order to establish recommended protocols for capture, chemical immobilization, anesthesia and radiotagging of free-ranging brown bears (*Ursus arctos*), wolves (*Canis lupus*), wolverines (*Gulo gulo*) and lynx (*Lynx lynx*). In addition, procedures to ensure proper sampling of biological materials for management, research and banking purposes should be included.

The current protocols are based on more than 2,000 captures of free-ranging brown bears, wolves, wolverines and lynx carried out during the last two decades in Scandinavia. Some of the results have been published as peer reviewed papers, conference presentations, theses, and reports. However, a large amount of data are still on file and will be published in the future. In addition, comprehensive reviews of the world literature on brown bears, wolves, wolverines and lynx have been carried out in order to include pertinent information from other sources.

Specific and mandatory requirements for sampling in Norway and Sweden, respectively, are outlined in the appendices.

The protocols have been approved by all ongoing research projects on brown bears, wolves, wolverines and lynx in Scandinavia.

We thank the contributors for their cooperative efforts. We also thank the Norwegian Directorate for Nature Management for their support.

This document will be updated on a regular basis and will be posted at the following websites: <http://www.dirnat.no/>, <http://skandulv.nina.no/>, <http://scandlynx.nina.no/> and <http://www.bearproject.info>

Tromsø and Uppsala, 21 August 2007

Jon M. Arnemo, DVM, PhD<sup>1</sup> and Åsa Fahlman, DVM, VetMedLic<sup>2</sup>

<sup>1</sup>*Professor of Wildlife Medicine, Section of Arctic Veterinary Medicine, Department of Food Safety and Infection Biology, Norwegian School of Veterinary Science, NO-9292 Tromsø, Norway ([jmarnemo@online.no](mailto:jmarnemo@online.no))*

<sup>2</sup>*Veterinary Officer, Department of Wildlife, Fish and Environment, National Veterinary Institute of Sweden, SE-751 89 Uppsala, Sweden, and PhD student at the Department of Clinical Sciences, Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, SE-750 07 Uppsala, Sweden ([asa\\_fahlman@hotmail.com](mailto:asa_fahlman@hotmail.com))*

---

Cover Photo: Jon M. Arnemo©

## INTRODUCTION

Chemical immobilization of wild animals is a form of veterinary anesthesia conducted under the most difficult circumstances. Anesthetic drugs are never completely devoid of toxicity and induction of anesthesia invariably carries a risk to the life of even healthy patients. The risk of severe side effects, injuries and death can never be completely eliminated. In addition, several immobilizing drugs are toxic and potentially lethal to humans.

Chemical immobilization of free-ranging wildlife should only be considered if it is necessary to accomplish research or management goals, and should be carried out by a team of professionals with proper training, experience and expertise in wildlife capture, veterinary anesthesia, animal handling and basic first aid and CPR techniques. If captures are carried out by darting from a helicopter, the skill of the pilot and the crew members is of paramount importance for a successful outcome.

All captures need to be properly planned. If possible, chemical immobilization of brown bears, wolves, wolverines and lynx should be carried out in winter or spring, on snow-covered ground. High ambient temperatures, open water, and bare ground make captures more difficult and will increase the risk of accidents and mortality. Although a number of different capture techniques are available, darting from a helicopter is the most efficient, safest and probably least stressful method in most species and situations. Net-gun capture of wild animals is not recommended due to the extreme risk of helicopter accidents and due to animal welfare considerations.

## DRUGS AND DOSES FOR CHEMICAL IMMOBILIZATION AND ANESTHESIA

### Brown bears

Brown bears are usually captured in early spring, shortly after they emerge from their dens. Although brown bears are sometimes chemically immobilized during summer or shortly before denning, such captures are more difficult due the lack of snow cover, and due to open water, high ambient temperatures and increased dose requirements.

Brown bears are darted from a helicopter using a remote drug delivery system (Dan-Inject<sup>®</sup>). Currently, the following standard doses of medetomidine (M) (Domitor<sup>®</sup>, Zalopine<sup>®</sup>) and tiletamine-zolazepam (TZ) (Zoletil<sup>®</sup>) are used for immobilization of free-ranging bears in April-May: Yearlings (15-45 kg) 1.25 mg M + 62.5 mg TZ; small bears (2-3 years, 45-70 kg) 2.5 mg M + 125 mg TZ; adult females and small males (70-120 kg) 5 mg M + 250 mg TZ; medium-sized adult males (120-200 kg) 10 mg M + 500 mg TZ; large males (> 200 kg) 15 mg M + 750 mg TZ. A fixed M:TZ ratio is used so that doses can be split or combined. The doses and darts are made up as follows:

- 1.25 mg M + 62.5 mg TZ (yearlings): 1 ml of Zalopine<sup>®</sup> and 1.8 ml of sterile water are used to dissolve 500 mg of Zoletil<sup>®</sup>; split into 8 doses; use 2 ml darts with 1.5 x 25 mm barbed needles (Dan-Inject<sup>®</sup>)
- 2.5 mg M + 125 mg ZT (small bears): 5 ml of Domitor<sup>®</sup> and 0.8 ml of sterile water are used to dissolve 500 mg of Zoletil<sup>®</sup>; split into 4 doses; use 2 ml darts with 2.0 x 30 mm barbed needles (Dan-Inject<sup>®</sup>)

- 5 mg M + 250 mg ZT (adult females and small males): 5 ml of Domitor<sup>®</sup> and 0.5 ml of Zalopine<sup>®</sup> are used to dissolve 500 mg of Zoletil<sup>®</sup>; split into 2 doses; use 3 ml darts and 2.0 x 40 mm barbed needles (Dan-Inject<sup>®</sup>)
- 10 mg M + 500 mg TZ (medium-sized adult males): 1 ml of Zalopine<sup>®</sup> and 1.5 ml of sterile water are used to dissolve 500 mg of Zoletil<sup>®</sup>; one dose; use 3 ml dart and 2.0 x 40 mm barbed needle (Dan-Inject<sup>®</sup>)
- 15 mg M + 750 mg TZ (large adult males): 1 ml of Zalopine<sup>®</sup> and 0.5 ml of sterile water are used to dissolve 500 mg of TZ; make up three vials that are split into two doses; use 3 ml darts and 2.0 x 40 mm barbed needles (Dan-Inject<sup>®</sup>)
- For capture of bears late in the fall: Consider increasing the dose by 25-50% and using longer needles.

Tiletamine-zolazepam used to be the drug combination of choice for immobilization of several bear species. Tiletamine-zolazepam has a wide margin of safety and has no major cardiopulmonary or thermoregulatory side effects in bears. The main disadvantage of this combination is extended recoveries. There is no reversal agent for tiletamine, and the use of a benzodiazepine antagonist like flumazenil (Anexate<sup>®</sup>), for reversal of zolazepam, in animals immobilized with high doses of tiletamine-zolazepam is not recommended. However, in combination with medetomidine, the effective dose of tiletamine-zolazepam can be reduced by as much as 75%, and atipamezole can then be used to shorten the recoveries. The physiologic effects of medetomidine-tiletamine-zolazepam have been studied in several bear species, and this drug combination is well tolerated by healthy individuals. Based on trials in captive brown bears scheduled for euthanasia, we consider that toxic effects from standard doses of medetomidine-tiletamine-zolazepam in healthy bears are very unlikely. A life-threatening situation should not be expected, even if a massive overdose (i.e. five times more than recommended) is administered by accident.

### **Wolves**

Wolves are usually immobilized from a helicopter in winter on snow-covered ground. All animals  $\geq 6$  months of age, regardless of sex and body mass, are darted with 500 mg tiletamine-zolazepam (Zoletil<sup>®</sup>) per animal using a remote drug delivery system (Dan-Inject<sup>®</sup>). A 3 ml dart syringe with a 1.5 x 25 mm barbed needle (Dan-Inject<sup>®</sup>) is used. Trapped wolves can be immobilized with the same dose. Mean (range) body weights in wolves  $> 18$  months old captured in Scandinavia were 48 (38-52) kg for males and 39 (35-44) kg for females. Juveniles 7-10 months old weighed 34 (24-42) kg.

A pilot study in free-ranging wolves darted from a helicopter (n = 28) with 5 mg of medetomidine (Zalopine<sup>®</sup>) + 250 mg of ketamine (Narketan 10<sup>®</sup>) showed that the animals were susceptible to hyperthermia. Medetomidine-ketamine has been used in captive wolves and in trapped free-ranging wolves (at a lower dose).

### **Wolverines**

Adult wolverines and juveniles ( $> 8$  months) are usually immobilized from a helicopter or in the den. Animals are darted with an initial dose of 4 mg medetomidine (Zalopine<sup>®</sup>) + 100 mg ketamine (Narketan 10<sup>®</sup>) per animal using a remote drug delivery system (Dan-Inject<sup>®</sup>). A 1.5 ml dart syringe with a 1.5 x 25 mm barbed needle (Dan-Inject<sup>®</sup>) is used. If the sex of an adult animal is known, an initial dose of 3 mg medetomidine (Zalopine<sup>®</sup>) + 75 mg ketamine (Narketan 10<sup>®</sup>) is sufficient for females (9-11 kg). The initial dose for adult males (14-16 kg) should be kept to 4 mg medetomidine (Zalopine<sup>®</sup>) + 100 mg ketamine (Narketan 10<sup>®</sup>). Cubs (up to 5-6 kg) are manually restrained, weighed and immobilized with 0.1 mg/kg

medetomidine (Domitor<sup>®</sup>) + 5 mg/kg ketamine (Ketalar<sup>®</sup>) i.m. (induces 30-40 min of safe immobilization). A blood gas study showed that arterial oxygenation was impaired in adult and juvenile wolverines anesthetized with the above doses. The anesthesia was conducted at high altitudes (500-1,300 m above sea level) and altitude was responsible for 30% of the reduction in arterial oxygenation. Further study is needed to evaluate whether a lower medetomidine dose would improve arterial oxygenation. Supplemental oxygen is recommended.

### **Lynx**

Adult lynx and juveniles (> 5 months) are either immobilized from a helicopter or captured using box traps or snares set around fresh roe deer kills. Hunting dogs are sometimes used to chase the lynx into a tree. Adults (males 18-26 kg, females 14-19 kg) are darted with an initial dose of 4 mg medetomidine (Zalopine<sup>®</sup>) + 100 mg ketamine (Narketan 10<sup>®</sup>) per animal using a remote drug delivery system (Dan-Inject<sup>®</sup>). In adults captured in box traps (calm animals) and in juveniles (6-12 months 9-16 kg, yearlings 12-21 kg), the doses can be reduced by 25 and 50%, respectively. A 1.5 ml dart syringe with a 1.5 x 25 mm barbed needle (Dan-Inject<sup>®</sup>) is used. Kittens (4-5 weeks of age; mean body mass 1.5 kg) are captured by hand in the lair, weighed and immobilized with 0.1 mg/kg medetomidine (0.1 ml Domitor<sup>®</sup>) + 5 mg/kg ketamine (0.1 ml Ketalar<sup>®</sup>) i.m.

### **Supplemental dose**

Supplemental dosing depends on the situation, species and whether anesthesia is required or not. Animals that are not down 15 minutes after the initial dose, are redarted with a full dose (all species). If the animal is down but incompletely immobilized, administration of additional drugs is usually necessary.

*Brown bears:* In large bears (adult females and adult and subadult males), darting with either a full dose or half the initial dose is recommended for safety reasons. In yearling bears and small bears 1 mg medetomidine (Domitor<sup>®</sup>) can be given i.m. by hand syringe injection.

*Wolves:* Wolves are usually easy to handle, even if they are not completely immobilized (which is often the case after darting with tiletamine-zolazepam). To reduce stress and to facilitate sampling, 1 mg medetomidine (Domitor<sup>®</sup>) i.m. is recommended to induce complete immobilization.

*Wolverines and lynx:* If the animal is down but incompletely immobilized, 25-50% of the initial dose can be given i.m. by hand syringe injection.

In case of a prolonged procedure or signs of spontaneous recovery, 0.5-1.0 mg medetomidine (Domitor<sup>®</sup>) i.m., can be used to keep juvenile and adult wolves, wolverines and lynx and yearling bears immobilized for another 15-30 minutes. For safety reasons, 2 mg medetomidine (Domitor<sup>®</sup>) should be combined with 1-2 mg/kg ketamine (Narketan 10<sup>®</sup>) in adult bears. If extra time is needed to finish surgery or other painful procedures, medetomidine-ketamine should always be administered. Due to the long elimination time, additional tiletamine-zolazepam should not be used, unless for safety reasons in large bears.

## CHASING, TRAPPING AND STRESS

Animals that have not been captured from (or chased by) a helicopter, are usually naïve when approached and darting can be performed within a few minutes of observation if the snow condition and the area are optimal (ice-covered lakes, clear-cuts, open terrain etc.). Animals that have been captured before (especially wolves) will usually run for cover when they hear the helicopter and are much more difficult to approach. To avoid stress and physiological side effects (hyperthermia, lactic acidemia) during immobilization, intensive chasing should be kept to a minimum, and the total time of pursuit should never exceed 30 minutes. In lynx, which are sometimes captured in box traps or foot snares or after being chased into a tree by hunting dogs, special care should be given to avoid accidents or physiologic side effects due to lengthy procedures.

## HANDLING AND MONITORING OF IMMOBILIZED ANIMALS

Immobilized animals should be monitored and clinically examined by professionals with experience in wildlife medicine. Possible side effects include respiratory depression (drug overdose in individuals with poor body condition, aspiration of vomitus/saliva, pneumothorax due to misplaced dart), vomiting (in wolves), and thermoregulatory dysfunction. If several animals are being captured at the same time (e.g.: members of a pack, family group), they should be brought together for monitoring and processing.

To prevent aspiration of saliva or vomitus, immobilized animals should be kept in lateral recumbency with the mouth and head low relative to the body. An eye gel (Viscotears<sup>®</sup>) should be applied to the cornea to prevent drying. Animals should be protected from direct sunlight into the eyes. Preferably, a blind-fold and ear plugs should be used.

Thermoregulation should be monitored by frequent measurements of the rectal temperature (RT). “Normal” RT in brown bears, wolves, wolverines and lynx is thought to be 38.0-39.0°C. Hyperthermic animals (RT > 40.0°C) should be cooled by applying snow (or water in summertime) to the axilla, groin, and/or tongue. In case of persistent hyperthermia or RT > 41.0°C i.v. fluid therapy should be initiated (10-15 ml/kg/hr of Ringer<sup>®</sup>-acetat). Oxygen supplementation is recommended to hyperthermic animals since the oxygen demand increases 10% for each °C increase in body temperature. Hypothermic animals (RT < 36.0°C) should be protected from wind and cold surfaces to avoid further cooling using a Wolverine Bag<sup>®</sup>. In case of prolonged immobilization and recovery, hypothermic animals should be warmed, and prewarmed fluid (38°C) (Ringer<sup>®</sup>-acetat) should be administered intravenously.

Cardiorespiratory function should be monitored using a pulse oximeter (Nellcor<sup>®</sup>) with the sensor (VetSat<sup>®</sup>) applied to the tongue. A relative arterial oxygen saturation (SpO<sub>2</sub>) > 90% is considered to be clinically acceptable in a field situation. A decreasing trend or SpO<sub>2</sub> < 90% indicate hypoxemia and supplementation with intranasal oxygen (2-5 liter/min) should be given to improve oxygenation. A portable oxygen cylinder should be part of the standard field equipment, as well as a laryngoscope, endotracheal tubes and a ventilation bag. The color of the mucous membranes in the mouth can be used to assess blood oxygenation. A pink or red color is normal; bluish membranes indicate hypoxemia. The capillary refill time (CRT) can be used to assess peripheral circulation. Normal CRT is 2 sec or less.

A small surgical kit for treating wounds and an electrical clipper should be part of the standard equipment.

## TAGGING, SAMPLING AND DOCUMENTATION

Most animals are captured for tagging or sampling purposes and should be processed according to the aim of the project. Capture data should be recorded according to an established animal capture form and photos should be taken (specific instruction for wolves).

Radiocollars (VHF, GPS or satellite) should be fitted according to the size, age and sex of the animal. The weight of the radiocollar should not exceed 2% of the animal's body mass.

*Brown bears:* The collar should be fitted so that it can be pulled on over the head. Drop-off collars or a break-away zone (double webbing in males, single in females) should be used on all growing bears and on bears of unknown age. For adult males, which may have a greater circumference of the neck than the head, consider clipping hair on the neck to avoid losing the collar. Ensure that it is possible to pass a flat hand between the collar and the neck.

*Wolves:* Minimum collar circumference should be 44.5 cm for females and 48.0 cm for males. Ensure that there is enough space for two fingers between the collar and the neck.

*Wolverines:* The circumference of the animal's head and neck should be measured before fitting the collar. The circumference of the collar should then be adjusted so it is slightly less than the circumference of the head, but larger than the circumference of the neck. Ensure that the collar is not too tight (make room for one finger between the neck and the collar) or that it can be pulled over the head of the animal. In some cases the difference in circumference of the head and neck is very small (especially in males) and fitting the collar can be difficult.

*Lynx:* The minimum collar circumference should be 26 cm for females and 30 cm for males. Ensure that at least one finger can be passed between the collar and the neck. Collars for juvenile males should have a break-away zone or an implant should be used if 30 cm is too great to be retained by the animal.

*All species:* The transmitter (VHF) should be activated by removing the magnet and should be tested with the receiver before the animal is released. Be sure that the GPS unit is working properly before any capture is initiated.

A microchip (e.g. Indexel<sup>®</sup>) should be implanted s.c. in the hump of brown bears, and in all the other species at the base of the right ear. The microchip should be tested with the scanner (Indexel<sup>®</sup>) after implantation. Application of ear tags and tattooing depend on the species, age of the animal, and aim of the project.

*Brown bears:* One plastic ear tag and a lip tattoo in all animals.

*Wolves:* Numbered plastic tags in both ears only in animals that are not radiocollared.

*Wolverines:* One aluminium ear tag (Sweden) and a lip tattoo in all animals.

*Lynx:* One plastic ear tag (Norway) and lip tattoo in all adult animals. An ear tattoo in 5-week-old kittens.

*All species:* Body measurements should be recorded according to the animal capture form.

Blood can be sampled from the jugular (all species), cephalic (wolves, lynx), or the femoral (all species) vein using evacuated plastic tubes and multisample needles (e.g. VenoSafe<sup>®</sup>, Venoject<sup>®</sup> II). The number of samples are specified in Appendix 1-4. Blood for genetic studies (5 ml EDTA) should be stored at  $-20^{\circ}\text{C}$  until shipment to the laboratory. Tubes without anticoagulant for serology should be kept at room temperature for 1-2 hours to ensure complete coagulation. Serum should then be separated by centrifugation (1500 g for at least 15 minutes) and transferred to 2 ml cryogenic vials (Nalgene<sup>®</sup>). Serum for banking (serology and back-up) is stored at  $-20^{\circ}\text{C}$  until shipment to the laboratory.

In brown bears and wolverines, the rudimentary first premolar is extracted for age determination. Local anesthesia (Lidokel-Adrenalin<sup>®</sup>) and carprofen (Rimadyl<sup>®</sup>) should be

administered before tooth extraction. The tooth is preserved in 96% alcohol in a 2 ml cryogenic vial (Nalgene<sup>®</sup>).

Hair should be collected with pliers and transferred to 15 ml sterile plastic tubes (Sarstedt<sup>®</sup>) (brown bears and wolves) or 5 ml sterile cryogenic vials (Nalgene<sup>®</sup>) (wolverines and lynx). Hair samples can be preserved by drying (in paper envelopes) or by freezing at -20°C. Skin biopsies are taken from the inside of the ear using a sterile dermal biopsy punch (Miltex<sup>®</sup>) (6 mm in brown bears and 4 mm in all other species) and transferred to 2 ml cryogenic vials (Nalgene<sup>®</sup>) and preserved by adding 96% ethanol.

In brown bears and wolves, feces is collected by inserting the index finger into the rectum using latex gloves. The feces is transferred to 50 ml sterile plastic tubes (Sarstedt<sup>®</sup>). In wolverines and lynx, feces is sampled by inserting a sterile cotton swab (Transwab<sup>®</sup>) into the rectum.

Depending on the situation and the study protocol, other biological materials should be sampled according to current standards in veterinary medicine or specific instructions from the laboratory.

### **ANALGESIA AND ANESTHESIA FOR SURGERY**

In brown bears, wolverines and lynx, surgical anesthesia is induced by the recommended immobilizing drugs and doses. For post operative analgesia, 4 mg/kg carprofen (Rimadyl<sup>®</sup>) is administered s.c. as soon as possible after immobilization is induced and before surgery is initiated (all species).

### **SURGICAL PROCEDURES FOR IMPLANTATION OF INTRAPERITONEAL RADIOTRANSMITTERS**

For surgery, the animal is kept in dorsal recumbency. An appropriate area caudal to the umbilicus is clipped and swabbed with chlorhexidine in 60% ethyl alcohol (Klorhexidin<sup>®</sup>). To avoid excessive heat loss at low ambient temperatures (below -10°C), clipping should not be done. Instead an antiseptic cream (Brulidine<sup>®</sup>) is rubbed into the fur along the midline and the hair is parted to expose the skin. For access to the peritoneal cavity, a ventral midline incision is made using standard surgical procedures. The weight of the implant (Telonics<sup>®</sup>) should not exceed 2% of the body mass of the animal. The radiotracer should be tested with the receiver before implantation. Implants should be gas sterilized (ethylene oxide) or disinfected by soaking in 10 mg/ml benzalkonium chloride (non proprietary) for at least 24 hours. They should be prewarmed and, in the case of chemically disinfected implants, thoroughly rinsed with sterile saline before being placed aseptically into the peritoneal cavity. The incision is closed in two layers with absorbable sutures (Vicryl<sup>®</sup>), using a simple interrupted pattern for the *Linea alba* (US 1 in all all bears except yearlings, US 0 in juvenile and adult wolves, wolverines, lynx and yearling bears and US 2-0 in wolf pups, wolverine cubs and lynx kittens; use a round needle) and a interrupted horizontal mattress pattern for the skin (US 0 in all bears except yearlings and US 2-0 in all other animals; use a cutting needle). The skin wound is covered with a spraydressing (OpSite<sup>®</sup>). Before surgery the animal is injected with a "long-acting" combination of procaine penicillin and benzathine penicillin at 100.000 IU/kg (100 mg/kg) i.m. (PENI-kél L.A. 15+15<sup>®</sup>) to reduce the risk of postoperative wound infections.

## **REVERSAL OF IMMOBILIZATION**

For reversal of immobilization in animals that have received medetomidine-combinations, 5 mg of atipamezole (Antisedan<sup>®</sup>) per mg of the total dose of medetomidine is administered i.m. or s.c. Due to the long elimination time of tiletamine-zolazepam, atipamezole should not be given until earliest 50-60 min after darting. In an emergency, atipamezole can be given at any time but recovery may then be rough with possible incoordination, excitation and convulsions. Such an animal can be calmed by administration of midazolam (Midazolam<sup>®</sup>) i.m. (suggested dose 0.1-0.2 mg/kg).

Immobilized animals can usually be left to recover undisturbed at the site of capture. Possible side effects and dangers during and immediately after recovery include vomiting (wolves), hypothermia (especially in animals with a small body mass relative to body surface or in case of extended procedures), hyperthermia (due to extensive chasing prior to capture, sun and/or high ambient temperatures), intraspecific strife (attack by pack members, males attacking other males, males trying to mount immobilized females in estrus, males attacking dependent young), open water, lack of fear, traffic, and poaching. All wolves should be observed by trained personnel until full recovery is evident. This may take 4-6 hours in wolves immobilized with tiletamine-zolazepam. It is highly recommended that all radio-instrumented animals are checked the day after capture.

## **OTHER TREATMENT**

Captured animals with health-threatening diseases should be treated according to accepted standards in veterinary medicine. In animals with severe or terminal illness, euthanasia should be considered. Vaccination of free-ranging carnivores in Scandinavia is currently not recommended.

## **NECROPSY PROCEDURES**

In case of a capture-related mortality, the carcass should be sent to a diagnostic laboratory for complete necropsy (Sweden: Statens Veterinärmedicinska Anstalt, Uppsala; Phone: + 46 18674000. Norway: Veterinærinstituttet, Trondheim; Phone: + 47 73580727). To ensure rapid cooling, skinning and evisceration should be considered. If transportation to the laboratory is not possible within 24-48 hours, the carcass should be frozen. As an alternative, a field necropsy can be carried out by a veterinarian after consultation with the laboratory.

## **LEGAL ASPECTS**

All captures have to be approved by the appropriate animal ethical committee (Norway: Utvalg for forsøk med dyr; Sweden: Försöksdjuretiska nämnden) and the wildlife management authority (Norway: Direktoratet for naturforvaltningen; Sweden: Naturvårdsverket). The use of motor vehicles may require special permits from local, regional and/or national authorities. Prior to starting capture activities, the police, animal welfare and wildlife authorities should be informed according to the permit. The use of radio-temlemetry equipment requires a permit (Norway: Post- og teletilsynet; Sweden: Post- och telestyrelsen).

Immobilizing agents are prescription drugs and must be used by or on the the order of a licensed veterinarian (Norway: Statens legemiddelverk; Sweden: Läkemedelsverket). Some of these drugs are also controlled substances, i.e. drugs that can be abused, for which specific regulations apply. In Norway, non-veterinarians can legally use immobilizing agents if a valid veterinarian/client/patient relationship is established; i.e. the veterinarian should ensure that the animal in question is under his/her care. In Sweden a special permit is required for non-veterinarians (Jordbruksverket).

Withdrawal times (brown bears): According to the current legislation in force in the European Union (EU), any substance to be used in food producing animals must be assessed by the European Medicines Evaluation Agency (EMA) in order to establish Maximum Residue Limits (MRLs). After assessment, substances may be listed in one of four Annexes of Council Regulation (EEC) No 2377/90 of 26 June 1990: Annex I – substances for which a full MRL has been fixed; Annex II – substances for which an MRL is not required; Annex III – substances for which a provisional MRL has been fixed; Annex IV – substances for which no MRL can be fixed. If the animal is a "food producing animal" (i.e. an animal, domestic or wild, captive or free-living, whose flesh or products are intended for human consumption), the veterinarian or the person acting under his/her direction may *only* administer a substance listed in Annex I, II, or III. Substances in Annex IV or substances that do not have an Annex entry (I, II, or III) may *not* be used in food producing animals. As of June 2001, very few of the drugs currently used for wildlife immobilization are authorized for use in food producing animals in the EU. In the EU, a withdrawal period is set within the procedure of granting a marketing authorization, i.e. either by the national authority concerned (Norway: Mattilsynet; Sweden: Läkemedelsverket) or, in case of a centrally authorized product, by the EMA. However, for substances that do not have an Annex entry, no marketing authorization can be granted for use in food producing animals.

## RECOMMENDED DRUGS AND EQUIPMENT

**Disclaimer:** The list does not indicate approval by any authorities or manufacturer for use on wildlife. Drugs and equipment mentioned in the text can be purchased from other manufacturers than those listed.

Anexate<sup>®</sup>, 0.1 mg/ml, F. Hoffmann-La Roche, Basel, Switzerland  
Antisedan<sup>®</sup>, 5 mg/ml, Orion Pharma Animal Health, Turku, Finland  
Brulidine<sup>®</sup>, Aventis Pharma, Oslo, Norway  
Dan-Inject<sup>®</sup>, Børkop, Denmark  
Domitor<sup>®</sup>, 1 mg/ml, and Zalopine<sup>®</sup> 10 mg/ml, Orion Pharma Animal Health, Turku, Finland  
Dopram<sup>®</sup>, Wyeth Lederle, Wyeth-Ayerst International Inc., Philadelphia, PA, USA  
Indexel<sup>®</sup>, Merial, Lyon, France  
Ketalar<sup>®</sup>, 50 mg/ml, Warner Lambert, Morris Plains, New Jersey, USA  
Klorhexidin, 5 mg/ml, Galderma Svenska AB, Bromma, Sweden  
Lidokel-Adrenalin<sup>®</sup> Kela Laboratoria NV, Hoogstraten, Belgium  
Midazolam<sup>®</sup>, 5 mg/ml, Alpharma AS, Oslo, Norway  
Miltex<sup>®</sup>, Miltex GmbH, Tuttlingen, Germany  
Nalgene<sup>®</sup>, Nalge Company, Rochester, NY, USA  
Narketan 10<sup>®</sup>, 100 mg/ml, Chassot, Dublin, Ireland  
Nellcor<sup>®</sup> NP-20, Nellcor Inc., Pleasanton, CA, USA  
OpSite<sup>®</sup>, Smith & Nephew Medical Limited, Hull, England  
PENI-kél L.A. 15+15<sup>®</sup>, Kela Laboratoria NV, Hoogstraten, Belgium  
Rimadyl<sup>®</sup>, 50 mg/ml, Orion Pharma Animal Health, Turku, Finland  
Ringer<sup>®</sup>-acetat, Pharmacia & Upjohn, Oslo, Norway  
Sartsedt<sup>®</sup>, Sarstedt AS, Ski, Norway  
Telonics<sup>®</sup>, Telonics Inc., Meza, AZ, USA  
Transwab<sup>®</sup>, Medical Wire & Equipment Co. Ltd., Corsham, Wiltshire, UK  
VetSat<sup>®</sup>, Nellcor Inc., Pleasanton, CA, USA  
Venoject<sup>®</sup> II, Terumo Europe N.V., Leuven, Belgium  
Vicryl<sup>®</sup>, Ethicon, Norderstadt, Germany  
Viscotears<sup>®</sup>, CIBA Vision AG, Hetlingen, Switzerland  
Wolverine Bag<sup>®</sup>, Jerven AS, Odda, Norway  
Zoletil<sup>®</sup>, 500 mg/vial, Virbac, Carros, France  
Zalopine<sup>®</sup>, 10 mg/ml, Orion Pharma Animal Health, Turku, Finland

## AUTHORITIES

Direktoratet for naturforvaltning, Norge: <http://www.dirnat.no/>

EMA: <http://www.emea.eu.int/>

Försöksdjuretiska nämnden, Sverige: <http://www.djurskyddsmyndigheten.se/jahia/Jahia/pid/2>

Läkemedelsverket, Sverige: <http://www.mpa.se/index.shtml>

Jordbruksverket, Sverige: <http://www.sjv.se/>

Mattilsynet, Norge: <http://www.mattilsynet.no/>

Naturvårdsverket, Sverige: <http://www.naturvardsverket.se/>

Post- og teletilsynet, Norway: <http://www.npt.no/>

Statens legemiddelverk, Norge: <http://www.legemiddelverket.no/>

Statens Veterinärmedicinska Anstalt, Sverige: <http://www.sva.se/>

Utvalg for forsøk med dyr, Norge - <http://www.fdu.no/fdu/om/>

Veterinærinstituttet, Norge: <http://www.vetinst.no/>

## BIBLIOGRAPHY

### General literature

- Anonymus. 2000 Report of the AVMA Panel on Euthanasia. *J Am Vet Med Assoc.* 2001; 218: 669-696.
- Anonymus. Guidelines for Euthanasia of Nondomestic Animals. American Association of Zoo Veterinarians, 2006.
- Adams HR, editor. *Veterinary Pharmacology and Therapeutics*. 8th ed. Ames: Iowa State University Press, 2001.
- Arnemo JM. Eutanasi av husdyr ved skyting. *Norsk Veterinærtidsskrift* 2005; 117: 457-463.
- Arnemo JM, Caulkett NA. Stress. In: West G, Heard D, editors. *Zoo Animal and Wildlife Anesthesia and Immobilization*. Blackwell Publications, 2007. **In press.**
- Bishop Y, editor. *The Veterinary Formulary*. 5th ed. London, UK: Pharmaceutical Press, 2001.
- Ford RB, Mazzaferro E, editors. *Kirk and Bistner's Handbook of Veterinary Procedures and Emergency Treatment*. 8th ed. Philadelphia, Pennsylvania, USA: Saunders, 2006.
- Caulkett NA, Arnemo JM. Chemical immobilization of free-ranging terrestrial mammals. In: Tranquilli WJ, Thurmon JC, Grimm K, editors. *Veterinary Anesthesia and Analgesia*. 4th ed. Blackwell Publishing, 2007. **In press.**
- Fossum TW, editor. *Small Animal Surgery*. 3rd Ed. St. Louis, Missouri, USA: Mosby, 2007.
- Hall LW, Clarke KW, Trim CM. *Veterinary Anaesthesia*. 10th ed. London: Baillière Tindall, 2001.
- Jessup DA, Clark R, Weaver RA, Kock MD. The safety and cost-effectiveness of net-gun capture of desert bighorn sheep (*Ovis canadensis nelsoni*). *Journal of Zoo Animal Medicine* 1988; 19: 208-213.
- Kreeger TJ, Arnemo JM. *Handbook of Wildlife Chemical Immobilization*. 3rd ed. Terry J. Kreeger, 2007.
- Nielsen L. *Chemical Immobilization of Wild and Exotic Animals*. Ames, Iowa, USA: Iowa State University Press, 1999.
- Plumb DC. *Veterinary Drug Handbook*. 4th ed. Ames, Iowa, USA: Iowa State University Press, 2002.
- Plunkett SJ. *Emergency Procedures for the Small Animal Veterinarian*. 2nd ed. London; UK: W. B. Saunders, 2001.

### Literature on brown bears, wolves, wolverines and lynx

- Arnemo JM, Ahlqvist P, Andersen R, Bertsen F, Ericsson G, Odden J, Brunberg S, Segerström P, Swenson JE. 2003. Risk of capture-related mortality in large free-ranging mammals: experiences from Scandinavia. *Wildlife Biology* 2006; 12: 109-113.
- Arnemo JM, Ahlqvist P, Liberg O, Sand H, Segerström P, Wabakken P. A new drug combination for reversible immobilization of free-ranging gray wolves [abstract/poster]. *Proceedings, World Wolf Congress; 25-28 September 2003; Banff, Canada; 64.*
- Arnemo JM, Dypsund P, Berntsen J, Schulze J, Wedul SJ, Ranheim B, Lundstein L. Use of intraperitoneal radiotransmitters in large carnivores [in Norwegian with English abstract]. *Norsk Veterinærtidsskrift* 1998; 110: 799-803.
- Arnemo JM, Dypsund P, Berntsen F, Schulze J, Wedul SJ, Ranheim B, Lundstein LG. Implantation of intraperitoneal radiotransmitters in brown bears (*Ursus arctos*), wolverines (*Gulo gulo*) and lynx (*Lynx lynx*): anesthetic and surgical procedures for field use [abstract]. *Proceedings of the 47th Annual Conference of the Wildlife Disease Association; 10-13 August 1998; Madison (WI), USA: 115.*
- Arnemo JM, Fahlman Å, Persson J, Segerström P. Anaesthetic and surgical protocols for implantation of intraperitoneal radiotransmitters in free-ranging wolverines (*Gulo gulo*) [oral presentation]. *1st International Symposium on Wolverine Research and Management; Jokkmokk, Sweden; 13-15 June 2005.*
- Arnemo JM, Linnell JDC, Wedul SJ, Ranheim B, Odden J, Andersen R. Use of intraperitoneal radiotransmitters in lynx kittens (*Lynx lynx*): anaesthesia, surgery and behaviour. *Wildlife Biology* 1999; 5: 245-250.

- Cattet MRL, Christison K, Caulkett NA, Stenhouse GB. Physiologic responses of grizzly bears to different methods of capture. *Journal of Wildlife Diseases* 2003; 39: 649-654.
- Cattet MRL, Caulkett NA, Stenhouse GB. Anesthesia of grizzly bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine. *Ursus* 2003; 14: 88-93.
- Fahlman Å. Anaesthesia of wild carnivores and primates – Physiological effects and reversibility of medetomidine and dissociative anaesthetics. Licentiate thesis. Uppsala, Sweden: Swedish University of Agricultural Sciences, 2005. ISBN 91-576-6859-0.  
[http://diss-epsilon.slu.se/archive/00000948/01/Final\\_Thesis\\_29\\_Aug.\\_2005.pdf](http://diss-epsilon.slu.se/archive/00000948/01/Final_Thesis_29_Aug._2005.pdf)
- Fahlman Å, Arnemo JM, Persson J, Segerström P, Nyman G. Physiological parameters during anaesthesia of free-ranging wolverines (*Gulo gulo*) in Sweden [oral presentation]. 1st International Symposium on Wolverine Research and Management; Jokkmokk, Sweden; 13-15 June 2005.
- Fernandez-Moran J. Mustelidae. In: Fowler ME, Miller RE, eds. *Zoo and Wild Animal Medicine*. 5th ed. St. Louis, Missouri, USA: Saunders, 2003; 501-516.
- Holz P, Holz RM, Barnett JEF. Effects of atropine on medetomidine-ketamine immobilization in the grey wolf (*Canis lupus*). *Journal of Zoo Wildlife Medicine* 1994; 25: 209-213.
- Kennedy-Stoskopf S. Canidae. In: Fowler ME, Miller RE, eds. *Zoo and Wild Animal Medicine*. 5th ed. St. Louis, Missouri, USA: Saunders, 2003: 482-491.
- Kreeger TJ. The internal wolf: physiology, pathology, and pharmacology. In: Mech LD, Boitani L, editors. *Wolves. Behavior, Ecology, and Conservation*. Chicago: The University of Chicago Press, 2003: 192-217.
- Madslie K. Use of intraperitoneal radiotransmitters in yearling female brown bears. Anaesthetic and surgical procedures. Student report. Oslo, Norway: Norwegian School of Veterinary Science, 2004.
- Madslie K, Arnemo JM, Swenson JE. Use of intraperitoneal radiotransmitters in yearling female brown bears. Anaesthetic and surgical procedures [poster]. 16th International Conference on Bear Research and Management; 27 September - 1 October 2005; Riva del Garda, Trentino, Italy.
- Ramsay E: Ursidae. In: Fowler ME, Miller RE, eds. *Zoo and Wild Animal Medicine*. 5th ed. St. Louis, Missouri, USA: Saunders, 2003; 523-538.
- Ranheim B, Andersen R, Persson J, Segerström P, Arnemo JM. Anesthesia of free-ranging Scandinavian wolverines (*Gulo gulo*) [abstract]. Proceedings, 8th World Congress of Veterinary Anesthesia; 16-20 September 2003; Knoxville, TN, USA; 147.
- Wack RF. Felidae. In: Fowler ME, Miller RE, eds. *Zoo and Wild Animal Medicine*. 5th ed. St. Louis, Missouri, USA: Saunders, 2003; 491-501.

## APPENDIX 1 – BROWN BEAR

### NORWAY AND SWEDEN (THE SCANDINAVIAN BROWN BEAR PROJECT\*)

| SAMPLE | NUMBER/VOLUME | RECIPIENT           |
|--------|---------------|---------------------|
| Tissue | 2             | SVA/Björnprojektet  |
| Tissue | 2             | DN/NINA             |
| Hair   | 1             | SVA/Björnprojektet  |
| Hair   | 1             | DN/NINA             |
| Feces  | 1             | NVH v/Jon M. Arnemo |
| Serum  | 2 ml          | SVA/Björnprojektet  |
| Serum  | 3 x 2 ml      | NVH v/Jon M. Arnemo |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |
|        |               |                     |

\* Contacts:

- Sven Brunberg: + 46 702737202; [noppi@algonet.se](mailto:noppi@algonet.se)
- Peter Segerström: + 46 702581120; [peter@solbritt.se](mailto:peter@solbritt.se)
- Arne Söderberg: + 46 702222766; [arne.soderberg@sva.se](mailto:arne.soderberg@sva.se)
- Jon M. Arnemo: + 47 99585019; [jmarnemo@online.no](mailto:jmarnemo@online.no)
- Jon E. Swenson: + 47 90744468; [jon.swenson@umb.no](mailto:jon.swenson@umb.no)
- Åsa Fahlman: + 46 706106388; [asa\\_fahlman@hotmail.com](mailto:asa_fahlman@hotmail.com)

## APPENDIX 2 – GRAY WOLF

### NORWAY AND SWEDEN (THE SCANDINAVIAN WOLF PROJECT)

| SAMPLE     | NUMBER/VOLUME | RECIPIENT           |
|------------|---------------|---------------------|
| Tissue     | 2             | DN/NINA             |
| Tissue     | 2             | Skandulv/Grimsö     |
| Hair       | 2             | DN/NINA             |
| Hair       | 2             | Skandulv/Grimsö     |
| Feces      | 1             | NVH v/Jon M. Arnemo |
| EDTA blood | 2 x 5 ml      | DN/NINA             |
| EDTA blood | 2 x 5 ml      | Skandulv/Grimsö     |
| Serum      | 8 x 2 ml      | NVH v/Jon M. Arnemo |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |
|            |               |                     |

\* Contacts:

- Per Ahlqvist: +46 702594445; [per.ahlqvist@nvb.slu.se](mailto:per.ahlqvist@nvb.slu.se)
- Jon M. Arnemo: +47 99585019; [jmarnemo@online.no](mailto:jmarnemo@online.no)
- Olof Liberg: +46 703949519; [olof.liberg@nvb.slu.se](mailto:olof.liberg@nvb.slu.se)
- Åsa Fahlman: + 46 706106388; [asa\\_fahlman@hotmail.com](mailto:asa_fahlman@hotmail.com)

### APPENDIX 3 – WOLVERINE

| SAMPLE        | NUMBER/VOLUME                    | RECIPIENT           |
|---------------|----------------------------------|---------------------|
| <b>Norway</b> |                                  |                     |
| Tissue        | 2                                | DN/NINA             |
| Hair          | 2                                | DN/NINA             |
| Feces         | 1                                | NVH v/Jon M. Arnemo |
| Serum         | 2 x 2 ml adults<br>1 x 2 ml cubs | NVH v/Jon M. Arnemo |
| <b>Sweden</b> |                                  |                     |
| Tissue        | 2                                | Järvprojektet       |
| Hair          | 1                                | Järvprojektet       |
| Feces         | 1                                | NVH v/Jon M. Arnemo |
| Serum         | 2 x 2 ml adults<br>1 x 2 ml cubs | NVH v/Jon M. Arnemo |
|               |                                  |                     |
|               |                                  |                     |
|               |                                  |                     |
|               |                                  |                     |
|               |                                  |                     |

\* Contacts, Norway:

- Roy Andersen: +47 92403331; [roy.andersen@nina.no](mailto:roy.andersen@nina.no)
- Jon M. Arnemo: +47 99585019; [jmarnemo@online.no](mailto:jmarnemo@online.no)
- Arild Landa: +47 93087930; [arild.landa@nina.no](mailto:arild.landa@nina.no)

\* Contacts, Sweden:

- Peter Segerström: +46 702581120; [peter@solbritt.se](mailto:peter@solbritt.se)
- Jens Persson: +46 706353605; [jens.persson@nvb.slu.se](mailto:jens.persson@nvb.slu.se)
- Åsa Fahlman: + 46 706106388; [asa\\_fahlman@hotmail.com](mailto:asa_fahlman@hotmail.com)

**APPENDIX 4 – LYNX**

| <b>SAMPLE</b> | <b>NUMBER/VOLUME</b>             | <b>RECIPIENT</b>    |
|---------------|----------------------------------|---------------------|
|               |                                  |                     |
| <b>Norway</b> |                                  |                     |
| Tissue        | 2                                | DN/NINA             |
| Hair          | 2                                | DN/NINA             |
| Feces         | 1                                | NVH v/Jon M. Arnemo |
| Serum         | 2 x 2 ml adults<br>1 x 2 ml cubs | NVH v/Jon M. Arnemo |
|               |                                  |                     |
| <b>Sweden</b> |                                  |                     |
| Tissue        | 2                                | Loprojektet         |
| Hair          | 1                                | Loprojektet         |
| Feces         | 1                                | NVH v/Jon M. Arnemo |
| Serum         | 2 x 2 ml adults<br>1 x 2 ml cubs | NVH v/Jon M. Arnemo |
|               |                                  |                     |
|               |                                  |                     |
|               |                                  |                     |
|               |                                  |                     |
|               |                                  |                     |

\* Contacts, Norway:

- John Odden: +47 91897175; [john.odden@nina.no](mailto:john.odden@nina.no)
- Jon M. Arnemo: +47 99585019; [jmarnemo@online.no](mailto:jmarnemo@online.no)

\* Contacts, Sweden:

- Per Ahlqvist: +46 702594445; [per.ahlqvist@nvb.slu.se](mailto:per.ahlqvist@nvb.slu.se)
- Kent Sköld: + 46 70 2030431; [kent.skold@nvb.slu.se](mailto:kent.skold@nvb.slu.se)
- Peter Segerström: +46 702581120; [peter@solbritt.se](mailto:peter@solbritt.se)
- Henrik Andrén: +46 702184406; [henrik.andren@nvb.slu.se](mailto:henrik.andren@nvb.slu.se)